Literature DB >> 26578706

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.

Jun Zhang1, Dongkyoo Park2, Dong M Shin3, Xingming Deng4.   

Abstract

Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%-30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment response and prognosis of lung cancer, developing an effective inhibitory approach is urgently needed. Here, we review different strategies currently being explored to target KRAS-mutant NSCLC, discuss opportunities and challenges, and also propose some novel methods and concepts with the promise of clinical application.
© The Author 2015. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Entities:  

Keywords:  KRAS; NSCLC; mutations; therapy

Mesh：

Substances：

Year:  2015        PMID： 26578706      PMCID： PMC4689161          DOI： 10.1093/abbs/gmv118

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN： 1672-9145            Impact factor:   3.848


  66 in total

Review 1.  Metabolic targets for cancer therapy.

Authors:  Lorenzo Galluzzi; Oliver Kepp; Matthew G Vander Heiden; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2013-10-11       Impact factor: 84.694

2.  Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.

Authors:  Dongkyoo Park; Andrew T Magis; Rui Li; Taofeek K Owonikoko; Gabriel L Sica; Shi-Yong Sun; Suresh S Ramalingam; Fadlo R Khuri; Walter J Curran; Xingming Deng
Journal:  Cancer Res       Date:  2013-07-03       Impact factor: 12.701

Review 3.  KRAS mutation: should we test for it, and does it matter?

Authors:  Patrick J Roberts; Thomas E Stinchcombe
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

4.  Cancer: Drug for an 'undruggable' protein.

Authors:  Nicole M Baker; Channing J Der
Journal:  Nature       Date:  2013-05-22       Impact factor: 49.962

5.  Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.

Authors:  Gunther Zimmermann; Björn Papke; Shehab Ismail; Nachiket Vartak; Anchal Chandra; Maike Hoffmann; Stephan A Hahn; Gemma Triola; Alfred Wittinghofer; Philippe I H Bastiaens; Herbert Waldmann
Journal:  Nature       Date:  2013-05-22       Impact factor: 49.962

6.  Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

Authors:  Ping Yuan; Koichi Ito; Rolando Perez-Lorenzo; Christina Del Guzzo; Jung Hyun Lee; Che-Hung Shen; Marcus W Bosenberg; Martin McMahon; Lewis C Cantley; Bin Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

7.  Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.

Authors:  Hyun Seok Kim; Saurabh Mendiratta; Jiyeon Kim; Chad Victor Pecot; Jill E Larsen; Iryna Zubovych; Bo Yeun Seo; Jimi Kim; Banu Eskiocak; Hannah Chung; Elizabeth McMillan; Sherry Wu; Jef De Brabander; Kakajan Komurov; Jason E Toombs; Shuguang Wei; Michael Peyton; Noelle Williams; Adi F Gazdar; Bruce A Posner; Rolf A Brekken; Anil K Sood; Ralph J Deberardinis; Michael G Roth; John D Minna; Michael A White
Journal:  Cell       Date:  2013-10-24       Impact factor: 41.582

8.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors:  Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

9.  Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Authors:  Denise A Yardley; Shinzaburo Noguchi; Kathleen I Pritchard; Howard A Burris; José Baselga; Michael Gnant; Gabriel N Hortobagyi; Mario Campone; Barbara Pistilli; Martine Piccart; Bohuslav Melichar; Katarina Petrakova; Francis P Arena; Frans Erdkamp; Wael A Harb; Wentao Feng; Ayelet Cahana; Tetiana Taran; David Lebwohl; Hope S Rugo
Journal:  Adv Ther       Date:  2013-10-25       Impact factor: 3.845

10.  Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death.

Authors:  Eran Schmukler; Eya Wolfson; Roni Haklai; Galit Elad-Sfadia; Yoel Kloog; Ronit Pinkas-Kramarski
Journal:  Oncotarget       Date:  2014-01-15
View more
  8 in total

1.  Chromosomal instability suppresses the growth of K-Ras-induced lung adenomas.

Authors:  Christopher D Laucius; Bernardo Orr; Duane A Compton
Journal:  Cell Cycle       Date:  2019-06-24       Impact factor: 4.534

2.  SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC.

Authors:  Christian F Ruiz; Emily D Montal; John A Haley; Alex J Bott; John D Haley
Journal:  FASEB J       Date:  2020-06-22       Impact factor: 5.834

3.  KRAS induces lung tumorigenesis through microRNAs modulation.

Authors:  Lei Shi; Justin Middleton; Young-Jun Jeon; Peter Magee; Dario Veneziano; Alessandro Laganà; Hui-Sun Leong; Sudhakar Sahoo; Matteo Fassan; Richard Booton; Rajesh Shah; Philip A J Crosbie; Michela Garofalo
Journal:  Cell Death Dis       Date:  2018-02-13       Impact factor: 8.469

Review 4.  Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

Authors:  Marzia Del Re; Eleonora Rofi; Giuliana Restante; Stefania Crucitta; Elena Arrigoni; Stefano Fogli; Massimo Di Maio; Iacopo Petrini; Romano Danesi
Journal:  Oncotarget       Date:  2017-12-21

5.  Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.

Authors:  Ke Xu; Dongkyoo Park; Andrew T Magis; Jun Zhang; Wei Zhou; Gabriel L Sica; Suresh S Ramalingam; Walter J Curran; Xingming Deng
Journal:  Mol Cancer       Date:  2019-04-10       Impact factor: 27.401

Review 6.  Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.

Authors:  Mahmoud Toulany
Journal:  Genes (Basel)       Date:  2019-01-04       Impact factor: 4.096

7.  KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study.

Authors:  Lindsay C Hewitt; Yuichi Saito; Tan Wang; Yoko Matsuda; Jan Oosting; Arnaldo N S Silva; Hayley L Slaney; Veerle Melotte; Gordon Hutchins; Patrick Tan; Takaki Yoshikawa; Tomio Arai; Heike I Grabsch
Journal:  Gastric Cancer       Date:  2019-05-20       Impact factor: 7.370

8.  Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?

Authors:  Nagla Abdel Karim; Asad Ullah; Peterson Pathrose; Hassana Fathallah; Ashley Perry; John C Morris; Jiang Wang; Sandra L Starnes
Journal:  Curr Oncol       Date:  2022-07-07       Impact factor: 3.109
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.